
ALZpath inks global licensing deal with Abbott to push blood tests for Alzheimer’s
A global license could speed blood-based Alzheimer’s diagnostics, forcing competitors to rethink timelines, partnerships, and trial plans.

Curating from trusted global sources…
Curated from trusted global sources, refined into briefing-grade analysis with executive summaries, insights, and bullet-point takeaways.

A global license could speed blood-based Alzheimer’s diagnostics, forcing competitors to rethink timelines, partnerships, and trial plans.

Feedstock allocation cleared on 24 June 2026, unlocking a world-scale expansion that lifts capacity by about 45%.

Chinese banks tighten retail access to precious metals as volatility spikes and gold falls below $4,000 for the first time since November.

Hazelnut Media acquired global rights for Dr. Rudrajit Roy’s Bengali film, launching with an education initiative for rural West Bengal.

The chip giant filed for a Nasdaq listing plan that could raise $29.4 billion, instantly reshaping investor expectations.

Fiscal Q3 results crush estimates, prove AI memory is rewriting Micron's margins, and change the momentum math for the whole chip stack.

The satellite and rocket company’s quick $25 billion borrowing move signals how it plans to finance scale after going public.

On Thursday, Accenture hit its biggest one-day drop on record after forecasting worries that AI could hollow out consulting.

CNBC says SpaceX’s shares surge following its IPO Friday, forcing investors to reprice what “space” and “AI” are worth.

Big IPO, bigger options debut: what it means for investors, risk teams, and anyone benchmarking market appetite.

SpaceX exercised its option for Cursor in an all-stock deal worth $60 billion, reshaping AI dealmaking expectations.

The valuation jump of $1T in a single day changes the reference point for risk capital and public-market comps.